Scientists at Sichuan University’s West China Hospital in Chengdu are set to be the first to inject people with T cells modified by the CRISPR–Cas9 gene-editing technique. The cells will be tested next month on lung cancer patients for whom chemotherapy, radiation therapy and other treatments have failed. Oncologist Lu Jianhua of Sichuan University says that he hopes his team can use this technique to treat a wide range of cancers. "And more importantly, I hope we can get positive data from the trial.” The phase 1 trial is designed to determine whether the technique is safe.
Scientists at Sichuan University’s West China Hospital in Chengdu are set to be the first to inject people with T cells modified by the CRISPR–Cas9 gene-editing technique. The cells will be tested next month on lung cancer patients for whom chemotherapy, radiation therapy and other treatments have failed. Oncologist Lu Jianhua of Sichuan University says that he hopes his team can use this technique to treat a wide range of cancers. The phase 1 trial is designed to determine whether the technique is safe.